Skip to content
Open access

CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia.

Nov 2026 · Blood · 0 citations
Medicine

Abstract

No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.